Brought to you by 
AstraZeneca investigates Taris Biomedical's bladder drug delivery system; options rights to cancer therapies
18 Aug 2014
Executive Summary
AstraZeneca PLC has taken an interest in the novel TARIS bladder drug delivery platform under development at Taris Biomedical Inc. The companies will work together using targeted therapeutics provided by AZ to study the device’s potential applications in the treatment of bladder cancer.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca investigates Taris Biomedical's bladder drug delivery system; options rights to cancer therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice